Information Provided By:
Fly News Breaks for January 14, 2019
Jan 14, 2019 | 07:59 EDT
Maxim analyst Anthony Vendetti lowered his price target on PAVmed to $3 following the FDA recommendation to "conduct human clinical studies to address any remaining substantial equivalence issues" for its CarpX program. The analyst notes that while the company intends to utilize its first-in-human clinical study in New Zealand plus a second site to satisfy the FDA's requirements, the CarpX timeline will be pushed out.
News For PAVM From the Last 2 Days
There are no results for your query PAVM